1. Home
  2. NSPR vs ELUT Comparison

NSPR vs ELUT Comparison

Compare NSPR & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NSPR
  • ELUT
  • Stock Information
  • Founded
  • NSPR 2005
  • ELUT 2015
  • Country
  • NSPR United States
  • ELUT United States
  • Employees
  • NSPR N/A
  • ELUT N/A
  • Industry
  • NSPR Medical/Dental Instruments
  • ELUT Medical Specialities
  • Sector
  • NSPR Health Care
  • ELUT Health Care
  • Exchange
  • NSPR Nasdaq
  • ELUT Nasdaq
  • Market Cap
  • NSPR 74.8M
  • ELUT 84.3M
  • IPO Year
  • NSPR N/A
  • ELUT 2020
  • Fundamental
  • Price
  • NSPR $2.69
  • ELUT $2.04
  • Analyst Decision
  • NSPR Strong Buy
  • ELUT Strong Buy
  • Analyst Count
  • NSPR 2
  • ELUT 2
  • Target Price
  • NSPR $4.50
  • ELUT $8.00
  • AVG Volume (30 Days)
  • NSPR 109.3K
  • ELUT 26.7K
  • Earning Date
  • NSPR 08-05-2025
  • ELUT 08-14-2025
  • Dividend Yield
  • NSPR N/A
  • ELUT N/A
  • EPS Growth
  • NSPR N/A
  • ELUT N/A
  • EPS
  • NSPR N/A
  • ELUT N/A
  • Revenue
  • NSPR $7,027,000.00
  • ELUT $23,711,000.00
  • Revenue This Year
  • NSPR $4.85
  • ELUT $20.10
  • Revenue Next Year
  • NSPR $113.47
  • ELUT $85.89
  • P/E Ratio
  • NSPR N/A
  • ELUT N/A
  • Revenue Growth
  • NSPR 8.49
  • ELUT N/A
  • 52 Week Low
  • NSPR $1.99
  • ELUT $1.61
  • 52 Week High
  • NSPR $3.80
  • ELUT $5.12
  • Technical
  • Relative Strength Index (RSI)
  • NSPR 62.76
  • ELUT 51.09
  • Support Level
  • NSPR $2.37
  • ELUT $1.85
  • Resistance Level
  • NSPR $2.92
  • ELUT $2.16
  • Average True Range (ATR)
  • NSPR 0.16
  • ELUT 0.22
  • MACD
  • NSPR 0.03
  • ELUT -0.02
  • Stochastic Oscillator
  • NSPR 66.18
  • ELUT 43.08

About NSPR InspireMD Inc.

InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.

About ELUT Elutia Inc.

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

Share on Social Networks: